Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Current Leases (2020 - 2026)

Lexaria Bioscience's Current Leases history spans 7 years, with the latest figure at $32060.0 for Q1 2026.

  • Quarterly results put Current Leases at $32060.0 for Q1 2026, up 9.28% from a year ago — trailing twelve months through Feb 2026 was $32060.0 (up 9.28% YoY), and the annual figure for FY2025 was $30417.0, up 8.45%.
  • Current Leases for Q1 2026 was $32060.0 at Lexaria Bioscience, up from $31101.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $42587.0 in Q3 2022 to a low of $25554.0 in Q4 2023.
  • The 5-year median for Current Leases is $29872.0 (2025), against an average of $31951.0.
  • The sharpest move saw Current Leases crashed 35.52% in 2023, then grew 12.75% in 2024.
  • Year by year, Current Leases stood at $39629.0 in 2022, then crashed by 35.52% to $25554.0 in 2023, then rose by 12.75% to $28812.0 in 2024, then increased by 7.94% to $31101.0 in 2025, then grew by 3.08% to $32060.0 in 2026.
  • According to Business Quant data, Current Leases over the past three periods came in at $32060.0, $31101.0, and $30417.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.